TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetastatic Cancer

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Eligible age

18+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.

Sponsor: University of Chicago

You may qualify if…

  • ✓ Patients with locally advandced or metastatic cancer whose physician has determined they are candidates for treatment with nivolumab or pembrolizumab
  • ✓ 18 years old or older
  • ✓ Measurable disease per RECIST criteria

You may not qualify if…

  • ✕ Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy.
  • ✕ Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal antibody in combination with either nivolumab or pembrolizumab.
  • ✕ Ipilimumab and nivolumab combination are not eligible for this trial.
  • ✕ (Note: Patients whose planned treatment is the combination of anti-PD-1 and tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of traditional cytotoxic chemotherapy and anti-PD-1 are eligible)

Where it's recruiting

Illinois

Chicago

Wisconsin

Madison

Source: ClinicalTrials.gov · NCT04295863 · last updated 2025-10-01